Since announcing the Comprehensive Economic and Trade Agreement (CETA) two weeks ago Harper’s Conservatives have repeatedly labelled those questioning the deal as “anti-trade”. But this Canada-European Union accord is one part trade and four parts ‘corporate bill of rights’.
The federal government won’t release internal documents that may predict potential higher drug costs for Canadians under new patent rules agreed to in the free-trade deal with Europe, Trade Minister Ed Fast says.
The far reaching provisions of the Comprehensive Economic and Trade Agreement between Canada and the European Union will have considerable impact on Canada’s IP regime.
The struggle for access to medicine presents a legal and ethical minefield for rich and poor countries alike—one that is being fought out as humanitarians challenge corporations over intellectual property rights.
India is facing an onslaught of political pressure from the U.S. government and pharmaceutical industry in retaliation for the country’s entirely legal actions to limit abusive patenting practices and increase access to affordable generic medicines
Thai trade representative Olarn Chaiprawat has given civil society groups a confirmation that "TRIPS-plus" and drug issues will not be included in the Thai-EU FTA negotiations.
Once again, our government is negotiating a trade deal in secret — and once again, the chorus of “free market” fundamentalists is assuring us that what’s good for lining corporate pockets must be good for us all.
Canada is pushing back against a campaign by activists trying to block what they say are onerous intellectual property rules that would raise the price of pharmaceuticals in poor countries.
As host to both the AIDS conference and TPP trade talks this month, Malaysia reportedly vows to reject a TPP trade agreement that harms access to medicines; other countries should follow suit, and Malaysia should be held to its pledge